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a  b  s  t  r  a  c  t
Deregulation  of angiogenesis  –  the  growth  of new  blood  vessels  from  an  existing  vasculature  – is a  main
driving  force  in  many  severe  human  diseases  including  cancer.  As such,  tumor  angiogenesis  is  important
for  delivering  oxygen  and  nutrients  to growing  tumors,  and  therefore  considered  an  essential  pathologic
feature  of cancer,  while  also  playing  a  key  role  in  enabling  other  aspects  of  tumor  pathology  such  as
metabolic  deregulation  and  tumor  dissemination/metastasis.  Recently,  inhibition  of tumor  angiogenesis
has  become  a clinical  anti-cancer  strategy  in line  with  chemotherapy,  radiotherapy  and surgery,  which
underscore  the critical  importance  of the angiogenic  switch  during  early  tumor  development.  Unfortu-
nately  the  clinically  approved  anti-angiogenic  drugs  in  use  today  are  only  effective  in a  subset  of  the
∗ Corresponding author at: Linköping University, Department of Medical and Health Sciences, Farmakologen, Ingång 68, Pl. 08, SE-581 85 Linköping, Sweden.
Tel.:  +46 101034004.
∗∗ Corresponding author at: Massachusetts General Hospital, Harvard Medical School, Department of Urology, 55 Fruit Street, Warren Building 324, Boston, MA 02114, USA.
Tel.:  +1 617 643 1956.
E-mail addresses: zwang0@partners.org (Z. Wang), lasse.jensen@liu.se (L.D. Jensen).
http://dx.doi.org/10.1016/j.semcancer.2015.01.001
1044-579X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Z. Wang et al. / Seminars in Cancer Biology 35 (2015) S224–S243 S225
patients,  and  many  who  initially  respond  develop  resistance  over  time.  Also,  some  of  the  anti-angiogenic
drugs  are  toxic  and  it would  be of great  importance  to identify  alternative  compounds,  which  could  over-
come  these  drawbacks  and  limitations  of the  currently  available  therapy.  Finding  “the  most  important
target”  may,  however,  prove  a very  challenging  approach  as  the  tumor  environment  is highly  diverse,
consisting  of  many  different  cell  types,  all of  which  may  contribute  to tumor  angiogenesis.  Furthermore,
the tumor  cells themselves  are  genetically  unstable,  leading  to a progressive  increase  in  the  number
of different  angiogenic  factors  produced  as the  cancer  progresses  to  advanced  stages.  As an  alternative
approach  to targeted  therapy,  options  to broadly  interfere  with  angiogenic  signals  by a mixture  of non-
toxic  natural  compound  with  pleiotropic  actions  were  viewed  by  this  team  as  an  opportunity  to  develop
a complementary  anti-angiogenesis  treatment  option.  As  a  part of  the  “Halifax  Project”  within  the  “Get-
ting to know  cancer”  framework,  we have  here,  based  on  a thorough  review  of  the  literature,  identiﬁed
10 important  aspects  of  tumor  angiogenesis  and  the  pathological  tumor  vasculature  which  would  be
well  suited  as targets  for anti-angiogenic  therapy:  (1)  endothelial  cell  migration/tip  cell formation,  (2)
structural  abnormalities  of  tumor  vessels,  (3)  hypoxia,  (4)  lymphangiogenesis,  (5)  elevated  interstitial
ﬂuid pressure,  (6)  poor  perfusion,  (7)  disrupted  circadian  rhythms,  (8)  tumor  promoting  inﬂammation,
(9) tumor  promoting  ﬁbroblasts  and  (10)  tumor  cell  metabolism/acidosis.  Following  this analysis,  we
scrutinized  the  available  literature  on broadly  acting  anti-angiogenic  natural  products,  with  a  focus  on
ﬁnding  qualitative  information  on phytochemicals  which  could  inhibit  these  targets  and  came  up  with
10 prototypical  phytochemical  compounds:  (1)  oleanolic  acid,  (2)  tripterine,  (3)  silibinin,  (4)  curcumin,
(5) epigallocatechin-gallate,  (6)  kaempferol,  (7)  melatonin,  (8) enterolactone,  (9)  withaferin  A and  (10)
resveratrol.  We  suggest  that  these  plant-derived  compounds  could  be  combined  to  constitute  a  broader
acting and  more  effective  inhibitory  cocktail  at doses  that would  not  be  likely  to cause  excessive  toxicity.
All the targets  and  phytochemical  approaches  were  further  cross-validated  against  their  effects  on  other
essential  tumorigenic  pathways  (based  on  the  “hallmarks”  of cancer)  in order  to discover  possible  syn-
ergies  or  potentially  harmful  interactions,  and  were  found  to  generally  also have  positive  involvement
in/effects  on  these  other  aspects  of tumor  biology.  The  aim  is that  this  discussion  could lead  to the  selection
of combinations  of  such  anti-angiogenic  compounds  which  could  be used  in  potent  anti-tumor  cocktails,
for enhanced  therapeutic  efﬁcacy,  reduced  toxicity  and circumvention  of  single-agent  anti-angiogenic
resistance,  as  well  as  for possible  use  in primary  or secondary  cancer  prevention  strategies.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction to tumor angiogenesis
Vessel formation in both health and disease occur through either
vasculogenesis – i.e. the recruitment of bone marrow-derived
endothelial progenitor cells to form new vessels, angiogenesis –
i.e. the sprouting and growth of new vessels from an existing vas-
culature or intussusception – i.e. the division or splitting of a blood
vessel into two or more new vessels [1]. The most common path-
way for neo-vessel growth in malignancy is angiogenesis (reviewed
in [2]) and the process is therefore called tumor angiogenesis.
In 1971, Judah Folkman ﬁrst advanced the hypothesis that tumor
growth depends on angiogenesis [3]. According to this hypoth-
esis, endothelial cells may  be switched from a resting state to a
rapid growth phase by a diffusible chemical signal emanating from
the tumor cells. The switch depends on increased production of
one or more positive regulators of angiogenesis, such as vascu-
lar endothelial growth factor (VEGF), ﬁbroblast growth factor-2
(FGF-2), interleukin-8 (IL-8), placental growth factor (PlGF), trans-
forming growth factor-beta (TGFbeta), platelet derived growth
factor (PDGF), angiopoietins (Angs) and others (reviewed in [4]).
These can be exported from tumor cells, mobilized from the
extracellular matrix, or released from host cells recruited to the
tumor. The switch may  also involve down-regulation of endoge-
nous inhibitors of angiogenesis such as endostatin, angiostatin or
thrombospondin (reviewed in [5]) and has thus been regarded as
the result of tipping the net balance between positive and negative
regulators. Mature microRNAs (miRNAs) can furthermore regulate
the levels of pro- or anti-angiogenic gene expression at the post-
transcriptional level (reviewed in [6]).
Angiogenic signals lead to the preferential differentiation of cer-
tain endothelial cells into so-called tip cells, which start to migrate
and exist at the leading front of the growing vessels. A num-
ber of factors including VEGF receptor (VEGFR)-3 (for lymphatic
endothelial cells), VEGFR-1 and–2 (for blood endothelial cells),
PDGF-B, and the Notch ligand delta-like ligand (Dll)-4 have been
shown to contribute to the endothelial tip cell phenotype [7,8]. In
healthy angiogenesis during development for example, the number
of tip-cells are limited leading to an orderly and organized expan-
sion of the vasculature. Endothelial cells located behind the tip
cell, so-called stalk cells, express other factors such as VEGFR-1
and Notch-1 and -4 which are important for inducing a quies-
cent state of these cells [9,10], maturation of the vascular wall,
lumen formation and to support perfusion. However, in patho-
logical angiogenesis including tumor angiogenesis this process is
usually disrupted by either excess production of pro-angiogenic
signals, lack of angiogenesis inhibitors, path-ﬁnding signals or mat-
uration factors, thus leading to excessive tip-cell formation and
migration of endothelial cells [11,12], which do not assume a qui-
escent phenotype associated with a healthy vasculature.
1.1. Structural and dysfunctional features of tumor blood vessels
As a result of the imbalance of angiogenic activators and
inhibitors, tumor blood vessels display many structural and func-
tional abnormalities including unusual leakiness (reviewed in [13]),
potential for rapid growth and remodeling [14], high tortuosity
and sinusoidal appearance (reviewed in [13]), poor coverage by
vascular supportive cells including pericytes and smooth muscle
cells [15], lack of arterial or venous identity leading to chaotic
blood ﬂow, poor functionality and perfusion [16], incorporation
of tumor cells into the endothelial wall, alternatively differentia-
tion of tumor stem-like cells to endothelial cells which contribute
to the tumor vasculature – a process known as vascular mimicry
[17]. These phenotypes, which can be considered “hallmarks of the
tumor vasculature”, mediate the dissemination of tumor cells in
the bloodstream and maintain the pathological characteristics of
the tumor microenvironment.
Tumor vessel density is furthermore very heterogeneous:
the highest values are found in the invading tumor edge,
where the density is 4–10 times greater than inside the tumor and
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the arrangement of vessels in the center of a tumor is much more
chaotic than at its edges (reviewed in [18]). Importantly, mechan-
ical stress generated by proliferating tumor cells also compress
vessels in tumors, with some vessels being oversized, whereas oth-
ers are more immature and smaller. These structural abnormalities
result in disturbed blood ﬂow, hypoxia, hyperpermeability, and ele-
vated interstitial pressure in many solid tumors (reviewed in [19]),
responsible, in turn, for impaired delivery of anti-cancer drugs as
well as oxygen, the former being critical for the success of chemo-
and the latter for radiation therapy.
1.2. Tumor hypoxia – an emerging target
There is a complex interrelationship between tumor hypoxia
and tumor angiogenesis. The production of several angiogenic
cytokines and growth factors is regulated by hypoxia, but as men-
tioned, tumor angiogenesis also further elevate tumor hypoxia. This
vicious circle is critical for driving many of the most pathogenic fea-
tures of cancer including poor treatment outcome and progression
to severe and metastatic disease.
Much of the dynamic regulation of this process involves
transcriptionally mediated changes that promote the enhanced
production of ligands and receptors, signaling aspects of both mito-
genic growth and directing the organization of an endothelial
network. While hypoxia and hypoxia signaling play major roles,
they are only two means by which angiogenesis can be triggered.
Other processes involving proteomic signaling, including those
effects directly attributed to the tumor biology [20], can also be
activated in support of the angiogenic response to various tissue
conditions.
Hypoxia in tumors develops in the form of chronic hypoxia,
resulting from long diffusion distances between (perfused) tumor
vessels, and/or of acute hypoxia, resulting from a transient collapse
of tumor vessels. One essential pathway activated in this series of
events is the activation of hypoxia inducible factors (HIFs), het-
erodimeric transcription factors composed from alpha and beta
subunits, which can be rapidly stabilized to ﬂuidly adapt to and
overcome the effects of a hypoxic environment. There are three
HIFalpha subunits, HIF1alpha, HIF2alpha, HIF3alpha, which are reg-
ulated in an oxygen dependent manner. HIFalpha subunits are
hydroxylated by prolyl hydroxylases (PHDs) [21] allowing HIFal-
pha subunits to be recognized by the von Hippel–Lindau (VHL)
ubiquitin-ligase complex [22]. VHL poly-ubiquitinates HIFalpha
subunits, leading to their subsequent proteasome-mediated degra-
dation. Under low oxygen conditions PHDs have reduced activity,
allowing for HIFalpha subunits to escape VHL-mediated degrada-
tion. HIFalpha subunits accumulate in the cytoplasm where they
bind HIFbeta to form a heterodimer that subsequently translocates
to the nucleus to activate transcription of target genes, including
genes important for various processes such as metabolism (glu-
cose transporter (GLUT)-1, hexokinase (HK)-1), cell growth (cyclin
(CCN)-D1 [23]) and also angiogenesis, such as erythropoietin, VEGF
and PDGF [24] (summarized in Fig. 1). In some cancers, mutations
of the machinery (such as VHL or other components) regulating
HIF stability can result in oxygen-independent constitutive stabi-
lization of the HIFalpha factors, and as a result these tumors are
notoriously highly vascularized [25].
Additional factors besides HIF-mediated VEGF transcriptional
activation have also been identiﬁed as promoting VEGF expression
under hypoxic conditions. Environmental stress as a result of low
oxygen and proper nutrient deprivation, such as glucose depriva-
tion, are capable of inducing VEGF mRNA stabilization resulting in
increased levels of the secreted ligand and angiogenic growth [26].
Hypoxic stress has also been described as inducing changes in miR-
NAs which can further inﬂuence the host microenvironment with
effects on angiogenesis [27].
Targeting hypoxia signaling is a promising approach to provide
more options for intervention in this critical pathway of tumor/host
biology. Additionally, HIFalpha factors can be regulated by mam-
malian target of rapamycin (mTOR) family translational signals
(Fig. 1), which provides a rich alternate source of targeting
(reviewed in [28]), and mTOR drugs are already in the market or
emerging.
1.3. Tumor lymphangiogenesis and lymphatic metastasis
Metastatic spread of tumor cells, via either blood or lymphatic
vascular systems, accounts for the majority of morbidity and mor-
tality in cancer patients. The presence of tumor cells within sentinel
lymph nodes (LN) that accept afferent lymphatic vessels draining
lymph from the primary tumor often indicates initial metastasis
that precedes (or predicts) distant metastasis to other organs. It
is also one of the most important markers for predicting patient
prognosis and deciding on therapeutic options [29,30].
Lymphangiogenesis, is often enhanced in malignant tumors, and
associated with positive LN metastasis as well as poor survival
of cancer patients [31–35]. Tumor-associated lymphangiogenesis
may  occur either at the immediate tumor periphery (peri-tumoral
lymphatics) or within the tumor mass (intra-tumoral lymphatics),
the former having been demonstrated to be functionally responsi-
ble for tumor cell dissemination [36,37]. Tumor lymphangiogenesis
is – as tumor blood- (or hem)angiogenesis – also regulated by a
balance of pro- and anti-lymphangiogenesis factors. The most fre-
quently studied tumor lymphangiogenic factors are members of the
VEGF family, most predominantly VEGF-C and -D, through interac-
tions with in particular VEGFR-3, with some additional evidence
for VEGF-A interacting with VEGFR-2 (reviewed in [38]). These
factors were found to increase LN metastasis and their expres-
sion correlated with poor prognosis in both animal models and
human cancers [39–44]. Other important lymphangiogenic factors
include FGF-2 and the key receptor FGF receptor (FGFR)-1 [45–47],
hepatocyte growth factor (HGF) and the cognate receptor c-met
[48], insulin-like growth factors (IGF)-1, -2 and IGF receptor (IGFR)
[49,50], EphrinB-2 and Eph receptor tyrosine kinase [51], Ang-1,
-2 and Tie2 [52], PDGF-BB and PDGF receptor (PDGFR)alpha and -
beta [53], growth hormone and the growth hormone receptor [54],
among others.
Tumor cells not only stimulate lymphangiogenesis within or
around the primary tumor site, but also have the capability to
induce neo-lymphangiogenesis in the LN itself, so as to prepare
a “pro-metastatic niche” for the spread of tumor cells [55–57].
Lymphangiogenesis at the sentinel LN appears to occur before-
hand and is further enhanced upon the arrival of metastatic cancer
cells [55,56], suggesting that the LN (possibly conditioned by cer-
tain tumor effectors, such as VEGF-A or VEGF-C) helps to provide a
favorable environment for tumor metastasis (reviewed in [58]).
As lymphangiogenesis is associated with increased LN metas-
tases (reviewed in [59]), blocking the process (or possibly inducing
lymphatic endothelial apoptosis/regression) may  serve as a favor-
able strategy to prevent lymph node metastasis. However, even
if the strategy may  result in fewer lymph-borne metastases over
time, there’s still the possibility that other biophysical functions are
affected by the alteration in lymphatic ﬂow within and surround-
ing the tumor. For example, a reduction in lymphatic drainage from
the tumor may  result in increased interstitial ﬂuid pressure (IFP)
within the tumor (reviewed in [60]). This in turn may  increase
tumor necrosis, hypoxia, and progression, while (at least tempo-
rarily) reducing the ability to deliver chemotherapy or other agents
via the compressed tumor vasculature.
Adding to the complexity of the regulation and functions of
tumor lymphatics, a variety of factors have been found to play
key roles in the separation of lymphatic vasculature from blood
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Fig. 1. Molecular mechanisms behind HIF regulation and responses in cells. The cellular oxygen sensing response is tightly regulated by a family of prolyl hydroxylases (PHD)
which  under normal oxygen conditions (normoxia; blue arrows) are responsible for hydroxylating proline residues on hypoxia inducible factor (HIF) alpha subunits. These
hydroxylated residues are recognized by a pVHL-E3 ubiquitin ligase complex, whereby HIFalpha subunits are marked for polyubiquitination and subsequent proteosomal
degradation. When oxygen levels are low (hypoxia; red arrow) PHDs cannot hydroxylate HIFalphas thereby allowing them to escape pVHL-mediated degradation. HIFalpha
subunits accumulate and bind to their heterodimeric partner, HIFbeta, translocate into the nucleus and activate a cascade of hypoxic signaling ﬁrst by the transcription of
various  target genes including microRNAs that are important for tumor promoting pathways. Alternatively, c-Src is also capable of activating HIFs by indirectly inhibiting
PHD  activity via the NADPH oxidase/Rac pathway. mTOR can also promote stabilization and HIF transcriptional activity. Critical points for therapeutic intervention include
the  use of c-Src and mTOR inhibitors to prevent HIFalpha accumulation and activation.
vessels during development. While these pathways may  also con-
tribute to neolymphatic outgrowth in tumors [61], the application
of inhibitory strategies to block the relevant pathways/effectors
(which include podoplanin, spleen tyrosine kinase (SYK)/SH2-
domain containing leukocyte protein of 76 kDa (SLP-76), Rac1/Ras
homology gene family member (Rho), and sprout-related EVH1-
domain containing (Spred)-1, -2 molecules) and examine the
effects on tumor lymphatic investment as well as tumor vascular
progression/remodeling has not been examined till date. Whether
this might disrupt (or complement the inhibition of) tumor lym-
phangiogenesis while maintaining the delivery of chemotherapy to
tumors during the relevant phase of treatment in the wider cancer
treatment program remains to be examined.
1.4. Disrupted circadian rhythms in cancer
Social and occupational jetlag is a consequence of the disruption
of our internal time-keeping system known as the circadian clock.
Social jetlag arise in people who are often rotating between day and
night shifts – often seen in healthcare workers, but a feature that is
becoming increasingly prevalent in people employed in other types
of jobs as well [62]. Occupational jetlag arises from traveling across
several time zones and thus exposing oneself to a prolonged, unnat-
ural day/light period, which is often experienced by airline pilots,
cabin personnel and globally acting businessmen. It is becoming
increasingly clear that such disruptions in the circadian rhythm are
associated with higher risk of various diseases, most prominently
sleep, metabolic, cardiovascular disorders and cancer [63,64]. In a
large epidemiological study following more than 100,000 Amer-
ican nurses over 10 years, it was found that nurses who  worked
rotating day and night shifts more than ﬁve times per month were
at signiﬁcantly increased risk of various types of cancer [65,66].
Recently several research groups have found that the circadian
rhythm is intimately involved in regulation of angiogenesis both
during development [64,67] as well as in disease [68–70]. As such,
circadian transcription factors were found to directly regulate VEGF
levels and were responsible for the elevated night-time spikes in
VEGF which are very important for physiological, developmental
angiogenesis [64,71]. Due to the wide-range of cancers that have
been associated with disrupted circadian rhythms, and the pro-
found role of angiogenesis in the development of malignancy, it is
tempting to speculate that circadian disruption may  be an impor-
tant player in pathological tumor angiogenesis.
2. Angiogenesis enables essential tumorigenic pathways
During tumor progression the amount and complexity of dereg-
ulated pathways which are essential for full blown malignancy,
increase. Whereas pathological deregulation of cell cycle control
in (often epithelial) cells is the ﬁrst step toward tumor develop-
ment, it is becoming increasingly clear that most of the essential
tumorigenic pathways that lead to cancer are dependent on patho-
logical deregulation of non-malignant host cells, and in particular
angiogenesis and tumor vascular functions. As such, the tumor
vasculature enables pathological tumor metabolism, genetic insta-
bility, inﬂammation, microenvironmental disruption and tumor
cell invasion/metastasis.
Tumors are often hypoxic in spite of high vascularization, due to
the poor structure and functionality of tumor blood vessels [11,12].
Intratumoral hypoxia is, somewhat paradoxically, a main cause of
high reactive oxygen species (ROS) formation within the tumor
cells (reviewed in [72]), and also coupled to pathological tumor
cell metabolism and acidosis (reviewed in [73,74]). Thus, improving
the quality of the tumor vasculature has been considered a way to
improve perfusion, reduce the pathological leakiness of the tumor
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vessels and reduce tumor hypoxia [16,19], which would also result
in a more stable tumor genome.
Tumor angiogenesis and pathological activation of the endothe-
lium, tumor vessel leakiness and hypoxia-induced apopto-
sis/necrosis in the tumor core, are resulting in a massive
recruitment and activation of inﬂammatory cells, such as lym-
phocytes, neutrophils, macrophages and mast cells. These cells
communicate by means of a complex network of intercellu-
lar signaling pathways mediated by surface adhesion molecules,
cytokines and their receptors. These inﬁltrating immune cells, gen-
erate an environment abundant in growth and angiogenic factors
and are implicated in enhancing cancer growth and subsequent
resistance to therapy [4,75]. The inﬂammatory cytokines inter-
leukin (IL)-1alpha and IL-1beta as well as a wide panel of other
signaling molecules produced by inﬁltrated inﬂammatory cells
including VEGF and matrix-metalloproteinases (MMPs) may  con-
tribute to angiogenesis, tumor proliferation, and local invasion of
cancer [76,77].
The deregulated tumor vasculature not only affects the recruit-
ment and activation of inﬂammatory cells, also cancer-associated
ﬁbroblasts (CAFs), myoﬁbroblasts and a number of other cell types,
which contribute to tumor progression and resistance to treatment
[14,78], is activated by endothelial cell- or hypoxia-derived factors
such as PDGF-BB. On the other hand, CAFs are also rich sources
of tumor angiogenic growth factors and cytokines, and thereby
play an active role in sustaining tumor angiogenesis and providing
resistance to anti-angiogenic therapy.
Tumors may  disseminate both by local invasion as well as via
blood or lymph vessels (hematologous or lymphatic dissemina-
tion). Clinically the latter two processes are the most problematic
in most tumor types as they lead to multifocal metastases. Also in
tumors that mostly disseminate locally (i.e. neurological cancers
for example), this dissemination often occurs via the vascula-
ture as tumor cells coopt the blood vessels and invade the
tissue by crawling along the endothelium [79]. Thus in all cases
blood and lymphatic vessels in or around the tumor are prereq-
uisite for tumor invasion and metastasis. Metastasis is further
enabled due to the poor structural integrity of the tumor blood
vessels and pathological angiogenesis-associated tumor hypoxia.
Recently, anti-angiogenic therapy has been reported to cause
an increased metastatic phenotype, possibly via elevated tumor
hypoxia and hypoxia-induced epithelial to mesenchymal transition
(EMT) [80–82]. Anti-angiogenic therapy may  however also increase
the metastatic potential of tumor cells through adaptive resistance
pathways not associated with hypoxia [83], indicating that anti-
angiogenic therapy-induced changes in the tumor phenotype may
lead to a more aggressive disease through a number of different
mechanisms. It is therefore not clear if targeting the tumor ves-
sels would be beneﬁcial or detrimental from a tumor metastasis
point of view. However, it may  be possible to merely reduce tumor
vascularization, improve the structure of the tumor blood vessels
and perfusion in the tumor and thus reduce the pathological char-
acteristics of the vessels, for example via sub-maximal dosing of
anti-angiogenic drugs [19]. There are still not much clinical data
supporting a beneﬁcial role for promoting formation of less patho-
logical vessels in tumors, and it is not known how to best achieve
this in patients.
3. Targets for anti-angiogenic therapy
The complexity in the angiogenic system provides many targets
for therapeutic intervention. On the other hand redundancy in the
angiogenic pathways raises the possibility of resistance to selective
therapeutic agents (reviewed in [84,85]). Examples of agents that
target circulating angiogenic factors include monoclonal antibodies
targeted against VEGF (bevacizumab) [86] or fusion proteins that
trap angiogenic factors (aﬂibercept or AMG386) [87]. Agents that
target synthesis of angiogenic factors include inhibitors of mTOR,
cyclo-oxygenase (COX) or heat shock protein 90 (HSP90) [88,89].
These groups of agents in addition to inhibiting the synthesis of
angiogenic factors can inhibit several other aspects of cancer biol-
ogy such as growth, resistance to apoptosis or metastasis. Agents
that target the angiogenic receptors are mainly tyrosine kinase
inhibitors (sorafenib, sunitinib, pazopanib, regorafenib or axitinib)
with multiple targets [90–92]. These agents are currently being
used in the treatment of several malignant diseases ranging from
breast, lung, gastric, colorectal, hepatocellular, glioblastoma, and
neuroendocrine tumors.
Similarly, there are several agents in clinical trials aimed at
blocking lymphangiogenesis/metastasis, mostly via neutralizing
VEGF-A, -C or -D-induced receptor activation. For example, a
major approach involves application of a variety of tyrosine kinase
inhibitors such as Ki23057, used to block gastric cancer spread
in mice through blockade of VEGFR3 autophosphorylation [93].
Other agents in clinical testing include PTK787/ZK222584 (Phase
III – colorectal cancer); BAY43-9006 (Phase II, multiple carcino-
mas); CEP7055 (Phase I – various malignancies); or JNJ-26483327
(Phase I for multiple advanced solid tumors). These, among other
anti-lymphangiogenic agents under study are reviewed in Ref. [59].
It is worthwhile mentioning that hormone- and chemotherapy
could also have anti-angiogenic activity, particularly metronomic
therapy which refers to the frequent, even daily, administra-
tion of chemotherapy (e.g. cyclophosphamide, methotrexate or
capecitabine) in doses below the maximum tolerated dose, for long
periods of time, with no prolonged drug-free breaks [94,95]. Other
chemotherapeutics, routinely used in clinic, may  also have anti-
angiogenic activity in vitro or in vivo [96] as: (1) paclitaxel [97],
doxorubicin and thalidomide [98] which seems to be mediated
via inhibition of VEGF and bFGF [99]; (2) celecoxib, which may
cause a time-dependent reduction in circulating angiogenic mark-
ers; (3) bisphosphonates may have anti-angiogenic effects [100] via
reduction of VEGF and PDGF serum levels [101]; (4) PI3K inhibitors
(including rapamycin analogues as temsirolimus (CCI-779) and
everolimus (RAD001)) decrease tumor angiogenesis [102–104] via
the inhibition of HIF-1alpha caused by the blockade of mTOR  activ-
ity.
Trials that have combined monoclonal antibodies and tyro-
sine kinase inhibitors have given rise to an increase in the side
effects proﬁle. A more rational approach would be to consider
combinations of agents that block production of angiogenic fac-
tors with such that target angiogenic factors or receptors. The
rationale behind such combinations include the fact that anti-
angiogenic agents can improve the delivery of cytotoxic agents
to the tumor site, may  alter hypoxia in the tumor and sensitize
it to chemotherapy or may  impede the ability of the tumor to
recover from cytotoxic effects of chemotherapeutic agents [105].
As tumors express more than one angiogenic cytokine and the
fact that during tumor progression the palette of tumor-derived
angiogenic factors grows more and more complex, any single
inhibitor would not be sufﬁcient for achieving sustained anti-tumor
responses [74]. We  hypothesize that simultaneously hitting mul-
tiple important aspects of tumor angiogenesis, each outlined in
detail in the sections above, with a cocktail of compounds might
create a more effective treatment. This could particularly be the
case for indications such as cancer prevention in high risk settings,
or maintenance therapies.
To facilitate the use of plant-derived compounds in cancer
treatment, we have selected 10 key mechanisms that lead to
pathological growth and functions of the tumor vasculature, such
as EC migration/tip cell formation, phenotypic changes in the
tumor microenvironment or pathogenic activation of stromal cells
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(macrophages or ﬁbroblasts). These pathways (top row in Table 1)
were selected as candidate targets for anti-angiogenic natural
compound-based therapy development.
4. Therapeutic potential of plant-derived compounds
During the last decades, phytochemicals have gained signif-
icant recognition for their potential therapeutic uses in cancer
[106–108]. Extensive research has revealed enormous potential
and exciting pharmacological properties of plant-based medicinal
compounds, and demonstrated synergistic effects in combination
with other agents to inhibit tumor angiogenesis, although the use
of phytochemicals alone is still a limited option for cancer treat-
ment. Some phytochemicals used in cancer therapies demonstrate
relatively low side-effects, and some even limit the side-effects
of chemotherapeutics or anti-angiogenic drugs. Fruits, vegetables,
cereals, pulses, legumes, herbs, spices and medicinal plants – such
as Artemisia annua (Chinese wormwood), Viscum album (Euro-
pean mistletoe), Curcuma longa (turmeric), Scutellaria baicalensis
(Chinese skullcap), Vitis vinifera (grape seed extract), Magnolia ofﬁ-
cinalis (Chinese magnolia tree), Camellia sinensis (green tea), Ginkgo
biloba (ginkgo), Poria cocos (tuckahoe), Zingiber ofﬁcinalis (ginger),
Panax ginseng (ginseng), Rabdosia rubescens hora (rabdosia), and
Chinese destagnation herbs – are all considered to be good sources
of phytochemicals exhibiting anti-cancer, and in particular anti-
angiogenesis activities. The active ingredients in these plants are
sometimes extracted and given in doses higher than what can be
achieved from consuming the plants of which they are derived in
order to give stronger therapeutic effect.
Many medicinal herbs and puriﬁed phytochemicals have
recently been evaluated for anti-lymphangiogenic and anti-
angiogenic properties in cancer (reviewed in [109–111]). The
potential mechanisms underlying their anti-lymphangiogenic fea-
tures involve (1) the control on cell proliferation, tube formation
and cell cycle progression of lymphatic endothelial cells, as exhib-
ited by multiple compounds fractionated from Korean and Japanese
Saussureae radix, Psoraleae semen and Aurantti fructus immaturus
[112]; (2) the inhibition of COX-2 expression and IL-1beta produc-
tion and the subsequent reduction in VEGF-C-induced VEGFR-3
phosphorylation, as observed with wogonin [113]; and (3) the
down-regulation of VEGFR3 and small GTPases, as well as the inhi-
bition of VEGFR3-mediated extracellular-signal regulated kinase
(ERK)-1 and -2 phosphorylation by cryptotanshinone [114]. The
mechanisms behind their anti-angiogenic effects include: (1) inhi-
bition of MMPs, (2) prevention of capillary sprout formation,
endothelial cell proliferation and migration, and (3) modulation of
angiogenic ligand/receptor mediated signaling pathways.
MMP  inhibition blocks the degradation of endothelial basement
membrane proteins, a process that otherwise leads to increased
permeability and poor structure and stability of the tumor vascula-
ture as well as release of sequestered angiogenic factors. However,
caution is warranted regarding the effects on MMP/tissue inhibitor
of metalloproteinases (TIMP) system as MMP  inhibitors in clinical
trials have failed and even induced worse survival rates compared
to placebo treated patients [115]. In addition, several experimen-
tal studies have shown potent anti-tumorigenic activities of many
MMPs including MMP-9 [116–121]. In the case of TIMPs both tumor
protective and tumor enhancing properties have been reported
[122–125]. For example, in breast cancer patients, high tumor
and serum levels of TIMP-1 have been associated with decreased
response to chemotherapy and consequently reduced survival
[126–128].
Targeting capillary sprout formation and directional endothe-
lial cell migration may  depend on diverse inhibitors of the Notch Ta
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signaling pathway, for which commercial drugs are in develop-
ment. There are also phytochemicals which exhibit such effects.
Finally, angiogenic signaling inhibitors include the modulation
of mitogen-activated protein kinase (MAPK) and Akt signaling,
inhibition of activator protein (AP)-1 activation, and the down-
regulation of VEGF, transforming growth factor (TGF)-beta, MMP-9,
as well as the upregulation of TIMP-1 which lead to reduction of
tumor cell invasion and blood vessel growth [129–132].
4.1. Tea polyphenols
Tea is one of the most highly consumed beverages in the
world and is rich in compounds exhibiting multiple health bene-
ﬁts (reviewed in [108]). The pharmacological action of tea is mainly
attributed to large quantities of polyphenolic compounds known as
catechins, which include epicatechin (EC), epigallocatechin (EGC),
epicatechin-3-gallate (ECG), and epigallocatechin-3-gallate (EGCG)
particularly in green tea and thearubigin and theaﬂavins in black
tea. Tea polyphenols have been shown to act on angiogenesis
through different signaling pathways. For instance, EGCG has been
found to directly inhibit capillary endothelial cell proliferation
at low concentrations, which illustrates the importance of this
molecule as an important tumor angiogenesis inhibitor [133]. EGCG
also inhibits VEGF production in MDA-MB231 breast cancer cells
and human umbilical vein endothelial cells which correlate with
the inhibition of protein kinase C, c-fos and c-jun RNA transcripts,
suggesting that AP-1 responsive regions present in the human
VEGF promoter may  be involved [134]. In neuroblastoma, ﬁbrosar-
coma, glioblastoma, prostate cancer, and human gastric cancer
cells, EGCG inhibited MMP-2 and MMP-9 while inducing the activ-
ity of their inhibitors TIMP-1 and TIMP-2 [135–138]. In human
breast cancer cells, EGCG treatment reduced MMP-2 activity and
the expression of focal adhesion kinase (FAK), membrane type-
1-MMP (MT1-MMP), nuclear factor (NF)-kappaB, VEGF, and the
adhesion of cells to the extracellular matrix (ECM) [139]. Simi-
lar signaling pathways have also been demonstrated in animal
studies. EGCG also targets urokinase plasminogen activator (u-PA),
leading to a down-regulation of VEGF production in tumor cells
and subsequent repression of AP-1, NF-kappaB and signal trans-
ducer and activator of transcription (STAT)-1 transcription factor
pathway [140,141]. EGCG furthermore inhibits aryl hydrocarbon
receptor (AhR)-AhR-mediated transcription by binding to HSP90.
Furthermore, a range of semi-synthetic and synthetic derivatives
are more potent than EGCG in a luciferase refolding assay for HSP90
activity [106]. In transgenic adenocarcinoma of the mouse prostate
(TRAMP) mice, green tea polyphenol infusion resulted in marked
inhibition of effectors of angiogenesis and metastasis, notably
VEGF, uPA, MMP-2, and MMP-9 [142]. In a dimethylaminoazoben-
zene (DAB) induced hepatoma model, administration of black tea
polyphenols not only reduced the incidence of invasion, but also
inhibited tumor hypoxia and angiogenesis [143]. In addition, EGCG
targets tissue plasminogen activator (t-PA), which is one of the
critical proteases that enable tumors to metastasize [144]. Several
studies based on cell culture and animal models further demon-
strated the cancer preventive function of tea, which is associated
not only with the inhibition of VEGF, NF-kappaB, c-fos and cyclin
D1 promoter activity, but also the decrease of Bcl-XL and the stabi-
lization of p53 [145,146].
4.2. Curcumin
Curcumin is a polyphenol isolated from Curcuma longa. As a yel-
low dye, curcumin has been used widely for centuries not only in
cooking, but also in traditional therapies for various diseases, espe-
cially inﬂammatory diseases. Curcumin and tetrahydro-curcumin,
one of its metabolites have been extensively investigated as
anti-inﬂammatory and anti-cancer molecules [147,148]. Curcumin
inhibits the expression of epidermal growth factor receptor (EGFR),
VEGFR-1, VEGFR-2 and VEGFR-3, and the kinase activity of Src and
FAK, which are responsible for the induction of angiogenic genes
as well as endothelial cell polarity and migration [149]. Curcumin
also reduces the MMP-2 and MMP-9 expression, along with the
suppression of growth and invasion potential of tumor cells in
culture and xenograft experiments [150]. Oral administration of
curcumin in nude mice xenografted with hepatocarcinoma cells led
to signiﬁcant lowering of tumor neocapillary density. The expres-
sion of angiogenic biomarkers COX-2 and serum levels of VEGF
were signiﬁcantly reduced in the curcumin-treated group [151].
This inhibition of both VEGF and VEGFR in different cancers, has
fueled the interest in this compound for further investigations as a
potential anti-angiogenesis agent [152].
4.3. Resveratrol
Resveratrol (3,4′,5-trihydroxy-trans-stilbene), a dietary
polyphenol derived from grapes, berries, peanuts and other
plant sources has been shown to affect several steps in the tumori-
genic process including tumor angiogenesis [153–155]. Resveratrol
inhibits capillary endothelial cell growth and new blood vessel
growth in animals [130]. It also prevents diethylnitrosamine-
initiated and phenobarbital-promoted hepatocarcinogenesis in
rats through interrupting cell proliferation, inducing apoptosis
[155] and impeding angiogenesis by suppressing VEGF expression
through down-regulation of HIF-1alpha [156]. In in vitro studies,
resveratrol was reported to inhibit cell proliferation of human
ovarian cancer cells and human osteosarcoma cells by attenuating
HIF-1alpha [157,158]. Through abrogation of VEGF-mediated
tyrosine phosphorylation of vascular endothelial cadherins and
beta-catenin, resveratrol further prevents cytokine-induced vascu-
lar leakage and tumor metastasis [130]. The underlying molecular
mechanisms include: blocking VEGF- and FGF-receptor-mediated
MAPK activation, inhibiting Akt- and MAPK-driven HIF-1alpha
basal expression and its induction by IGF-1, stimulating the protea-
somal degradation of HIF-1alpha, inhibiting phosphatidyl inositol
(PI)-3K/Akt and Ras/mitogen/extracellular signal-regulated kinase
(MEK)/ERK pathways, and activation of forkhead box (FOX)O
transcription factors [130,157–159].
Furthermore, the synthetic stilbene derivatives of resveratrol
have stronger inhibitory effect on angiogenesis than resveratrol,
as measured by cell proliferation and tube formation in bovine
aorta endothelial cells [160]. For instance, the stilbene derivative
rhapoantigenin inhibits angiogenesis-induction by prostate cancer
cells through HIF-1alpha degradation [161]. Likewise, resveratrol
and a series of natural or synthetic stilbenes inhibit the growth
of colon cancer-xenografts in mice through attenuation of VEGF
and pro-MMP-9 [162]. While pre-clinical studies have been done
broadly and for many different indications, resveratrol is yet to be
clinically assessed for safety and prevention of cancer as well as in
cancer therapeutic regimens.
4.4. Flavonoids
In the family of polyphenols, ﬂavonoids have been found to sup-
press tumorigenesis via anti-angiogenesis, anti-oxidant as well as
anti-proliferation effects on tumor- as well as tumor-associated
stromal cells including endothelial cells [163,164]. Flavonoids,
including ﬂavones (apigenin, luteolin), ﬂavanols (quercetin,
kaempferol), ﬂavanones (hesperetin, naringenin), anthocyanins
(cyanidin, delphinidin) and isoﬂavones (geneistein, daidzein)
function as scavengers of free radicals and thus inhibit ROS for-
mation and hypoxia-signaling cascades, modulate COX-2, and
inhibit EGFR, IGFR-1 and NF-kappaB signaling pathways [165].
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For instance, kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-
4H-1-benzopyran-4-one) has been reported to reduce ovarian
cancer risk [166,167]. Kaempferol exhibits anti-inﬂammatory
effects through inhibition of IL-4 [168] and COX-2 expression
by suppressing Src kinase [169], and further down-regulates the
NF-kappaB pathway [170]. Flavonoids furthermore inhibit angio-
genesis through multiple mechanisms, including interaction with
the COX-2 and lipoxygenase-5 enzymes, EGFR and the human
epidermal growth factor receptor (HER)-2 intracellular signaling
pathway [171].
Silymarin is the standardized extract of the seeds of Silibum
marianum (milk thistle). Silibinin, the major active constituent was
initially developed as a hepatoprotective product. Recently, how-
ever, it has been reported that silibinin inhibit MMP-2 expression
and suppresses capillary formation of human umbilical cord venous
endothelial cells (HUVECs) on matrigel [172–174]. Other natu-
rally occurring ﬂavonoids have been showing anti-angiogenesis
and anti-oxidant effects via interference with diverse signaling
pathways. For example, myricetin has been shown to inhibit
inhibitor of kappaB kinase (IKK) kinase activity and prevent degra-
dation of I-kappaBalpha and I-kappakBbeta in tumor necrosis factor
(TNF)-activated endothelial cells [175]. Sulforaphane has been
demonstrated to inhibit VEGFR2 at the transcriptional level [176].
Studies also showed that licochalcone A (LicA), a major con-
stituent of Glycyrrhiza inﬂata,  signiﬁcantly inhibits proliferation,
migration, and tube formation of HUVECs as well as microves-
sel growth from rat aortic rings. Furthermore, LicA signiﬁcantly
inhibits the growth of CT-26 colon cancer implants in BALB/c mice,
with fewer CD31- and Ki-67-positive cells but more apoptotic
cells [177]. Isoliquiritigenin, another ﬂavonoid found in G. inﬂata
inhibits cell migration and invasion of human prostate cancer cells
(DU145 and LNCaP) mediated by decreased c-Jun N-terminal kinase
(JNK)/AP-1 signaling and reduced production of proangiogenic fac-
tors [178]. Taken together, these ﬁndings provide evidence that
ﬂavonoids inhibit angiogenesis in vitro and in vivo, via antioxidant,
anti-inﬂammatory and anti-angiogenic signaling pathways.
4.5. Terpenoids
Terpenoids are the most diverse constituents in many plant
species. They form a group of natural substances which includes
steroids and sterols, exhibiting anti-inﬂammatory and anti-
carcinogenic properties [20,179–182].
The bioactive terpenoid, tripterine, also known as celastrol,
a quinine methide triterpenoid is the most abundant bioac-
tive compound derived from the root of Trypterigium wilfordii.
Tripterine modulates the expression of proteins with angiogenic
and metastatic activities (MMP-9, intercellular adhesion molecule
(ICAM)-1, VEGF) and those involved in cell survival (inhibitor
of apoptosis protein (IAP)-1, X-linked (X)-IAP, B-cell lymphoma
(Bcl)-2, Bcl-xL, ﬂice inhibitory protein (cFLIP), survivin) or cell
proliferation (cyclin D1, COX-2) in tumor cells [183,184]. These
ﬁndings provide evidence for its potential anti-angiogenic and anti-
tumor activities.
Escin is a pentacyclic triterpenoid which is isolated from the
seeds of Aesculus hippocastanum (horse chestnuts) [185]. Escin
sodium has been shown to inhibit endothelial cell migration and
motility. This anti-angiogenic activity was mediated partly by
inhibiting ERK and p38 MAPK pathways, which are involved in cell
proliferation, motility and apoptosis [186].
Withaferin A is a major steroidal lactone constituent of the
medicinal plant Withania somnifera,  consumed as a dietary sup-
plement around the world and used in the treatment of tumors
and inﬂammation in several Asian countries [187]. Withaferin A
exerts potent anti-angiogenic activity in vivo even at 500-times
lower dose than that exerting direct anti-tumor activity [188,189].
Similar trends toward a more potent anti-angiogenic rather than
anti-tumorigenic effects are also observed for other phytochemi-
cals (such as tubulysin A as discussed below) suggesting that the
vasculature may  be a good target for treatments with phytochem-
icals.
In addition, carotenoids have anti-cancer activity in breast can-
cer animal models. The carotenoid group includes alpha-carotene,
beta-carotene, lycopene, lutein, astaxanthin, cryptoxanthin and
zeaxanthin [190,191]. The anti-oxidant action is one of the
presumed mechanisms for the anti-angiogenic effects of the
carotenoids.
4.6. Phytoestrogens
Phytoestrogens are plant compounds which are structurally
similar to estrogen. Thereby, these compounds may  have beneﬁ-
cial effects in prevention of steroid hormone-dependent cancers
such as breast and prostate cancer. There are two  major classes
of phytoestrogens, isoﬂavones, found in soy at high concentra-
tions, and lignans, found in ﬂaxseed in high amounts. Lignans are
ubiquitous compounds in plant material and are present in seeds,
whole grains, vegetables, and berries [192–194]. Genistein (GEN),
the representative of isoﬂavone, and enterolactone (ENL) is the
main active and most potent metabolite of lignin, both have ago-
nistic and antagonistic actions in cancer, depending on their dose
and the tumor-type. In Eastern societies, the diet contains large
amounts of phytoestrogens, and accordingly, the incidence of can-
cers such as breast cancer and prostate cancer is low [195,196]. In
the diet, phytoestrogens are consumed in combination and vari-
ous phytoestrogens may  have different effects on tumor biology.
GEN has been shown to reduce the angiogenic and metastatic
potential of various cancer cell types in vitro [197]. However, the
pro-estrogenic effects of GEN in breast cancer [198] suggest that
caution with this particular phytoestrogen in hormone-dependent
cancers is warranted. In addition, as the major circulating lignan in
the human body, the majority of dietary lignans are converted into
ENL. ENL inhibits cancer growth in vivo by enhancing apoptosis,
inhibiting angiogenesis, and reducing inﬂammation without severe
side-effects [199–201].
5. Prophylaxis, pharmacodynamics and safety issues
As outlined above, there is convincing evidence in support
of beneﬁcial effects of phytochemicals in cancer-related path-
ways, particularly with regard to anti-angiogenesis. Furthermore,
many natural molecules exhibit potent anti-angiogenic activity
similar to the synthetically produced drugs currently in clinical
use. For example curcumin, EGCG, ﬁnasteride and barrigtozenol
demonstrated comparable effects on VEGF receptor inactivation as
pazopanib, the reference drug [202]. 10 M curcumin signiﬁcantly
inhibited VEGF-induced HUVEC migration to a higher degree (52%)
than the same concentration of a synthetic anti-angiogenic agent –
the selective PDE4 inhibitor rolipram (41%) [203]. Furthermore, the
EC50 dose–responses are usually lower for anti-angiogenic effects
vs. cytotoxic effects on cancer cells both for synthetic and nat-
ural products. For example tubulysin A, a natural compound of
myxobacterial origin, which inhibits tubulin polymerization has an
EC50 for endothelial cell proliferation of 1.2 nM and up to 3.0 nM
for cancer cell proliferation [204,205]. The synthetic derivates of
tubulysin A, AU816 and JB337, exhibit similar differences; EC50 of
AU816 for endothelial cell proliferation is 4.4 nM, whereas inhibi-
tion of cancer cell proliferation is 10 nM and for JB337 the EC50
levels are 14 nM compared to 100 nM for endothelial and cancer
cell proliferation, respectively [204,206].
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Since most phytochemicals have poor water solubility and
low bioavailability, the use of nano-carriers allows the prepa-
ration of these compounds in solid or liquid formulations with
highly improved pharmacodynamics properties. Such encapsula-
tion, however, render these natural compounds semi-synthetic,
but the active ingredients in such preparations are still all-natural.
Often, delivery mechanisms based on nano-carriers may  in addi-
tion to improved pharmacokinetics also lead to improve targeting
of the active compounds to the appropriate – i.e. tumor – site.
For example in the case of anti-lymphatic drugs, nano-carriers,
which are not able to cross the endothelium by themselves, but
extravasate in tumors due to the high leakiness of tumor blood
vessels, accumulate in draining intra-tumoral lymphatics and thus
serve as a means to target the drugs to the leaky tumor environ-
ment. Nanoparticles made of biodegradable polymers have been
utilized recently for the delivery of anti-cancer phytochemicals
[207,208]. Siddiqui et al. [209] reported that nano-encapsulated
EGCG retains its biological effectiveness, with over 10-fold dose
advantage compared to nonencapsulated EGCG for exerting its pro-
apoptotic, and anti-angiogenic effects. Encapsulation of kaempferol
with nanoparticles signiﬁcantly reduces cancer cell viability, as
does coating it onto poly(dl-lactic acid-coglycolic acid) (PLGA)
nanoparticles [210]. Furthermore, nano-encapsulated curcumin
has increased in vivo tumor anti-angiogenic activity relative to
its non-encapsulated form [211]. Solid lipid nano-encapsulation
of berbarine also increased inhibition of cancer cell proliferation,
cell cycle arrest, and apoptosis [212]. Nano-encapsulation therefore
seems like a promising strategy to overcome pharmacodynamics
issues associated with many phytochemicals.
The bioavailability, efﬁcacy and stability of phytochemicals
may  also be increased by synthetic derivation – a procedure
in which functional groups are added to or removed from the
natural phytochemical, leading to improved pharmacokinetics of
the resulting semi-synthetic phytochemical drug, while retaining
or even improving its biological effects. Such an approach has
proven particularly useful in rendering oleanolic acid attractive
for therapeutic applications. Oleanolic acid is an oleanane-type
triterpenoid that is widely found in dietary and medicinal plants
[213]. Studies demonstrated that oleanolic acid has anti-angiogenic
effects on bovine aortic endothelial cells and in the chick embryo
chorioallantoic membrane assay [214]. However, 2-cyano-3,12-
dioxoolean-1,9-dien-28-oic acid (CDDO), the synthetic derivative
of oleanolic acid, its C-28 methyl ester (CDDO-Me) and C-28
imidazole (CDDO-Im), are all shown to be potent inhibitors of
angiogenesis in the Matrigel sponge assay and in tumors estab-
lished from immortalized Kaposi’s sarcoma cells. These compounds
prevent endothelial cell tubulogenesis on Matrigel and inhibit the
VEGF-induced ERK-1 and -2 pathway in HUVECs [214,215]. It has
been suggested that COX-2 overexpression may  lead to increased
tumor angiogenesis [216,217]. Therefore, inhibition of the COX-2
pathway might prevent carcinogenesis and angiogenesis via anti-
inﬂammatory signaling. For example, CDDO-Me has been shown as
an effective inhibitor of COX-2 and tumor growth in breast cancer
models in mice.
These studies underscore the importance of phytochemicals
and semi-synthetic derivatives or formulations of phytochemicals,
as a novel anti-tumor treatment option in the future. More-
over, their anti-angiogenic properties could help to optimize the
effectiveness of existing chemotherapeutic drugs. The use of phyto-
chemicals as adjuvants in combination with anti-angiogenic drugs
is promising. For example, tumor hypoxia can be a deleterious
result of anti-angiogenic cancer treatment leading to changes in
cellular metabolism [73,74,218], elevated intracellular ROS-levels
[72], de-differentiation of tumor cells and increased metastatic
propensity [218,219]. These hypoxia-induced pathways can be
treated by various phytochemical antioxidants including EGCG,
melatonin, resveratrol and silibinin [143,157,220–223]. While this
could provide a strong argument for synergy by combining such
agents, it was traditionally believed that hypoxia should be the
very goal of anti-angiogenic treatment and an important inducer of
tumor cell apoptosis [224,225]. Therefore addition of such antiox-
idants may  reduce the hypoxia-induced cell death, as it does for
non-malignant cells [226,227], potentially leading to a poorer out-
come from the anti-angiogenic treatment. Also in the interaction
between tumor inﬂammation and angiogenesis the combination
of anti-inﬂammatory phytochemicals with anti-angiogenic drugs
may  provide a potential for synergy as inﬂammatory cells are
considered a source of alternative angiogenic factors and thus
important for evasive resistance [4]. However, some inﬂammatory
cells are thought to be anti-tumorigenic and important for tumor
clearance [228,229], and inhibiting them could lead to antagonis-
tic interactions in such combinations. Thus each combination of
phytochemicals and other treatment options should be thoroughly
tested in pre-clinical and clinical trials before adopted by medical
practitioners.
Tumor angiogenesis is not only required for late-stage progres-
sive disease, but is crucial even for initial growth of the tumor
to clinically detectable masses. Therefore, the inhibition of angio-
genesis has been proposed as an important preventive strategy
[230]. This idea, also known as angioprevention, is highly efﬁca-
cious in preventing tumor growth in animal models [156,231].
Angioprevention should be achieved using non-toxic agents such
as phytochemicals, as they are often consumed on a daily basis.
Ideally, we  should however also aim to achieve anti-angiogenic
treatment efﬁcacy using phytochemical agents at sufﬁciently low
doses to keep toxic side-effects are kept to a minimum. Thus safety
concerns should weigh in heavily when deciding on the most
appropriate drugs for anti-angiogenic treatment in cancer. Here, we
intend to identify 10 suitable, prototypical anti-angiogenic thera-
peutic approaches based on phytochemicals that have proven to
be effective against our previously deﬁned targets. We  aimed at
ﬁnding compounds that are free from intellectual property con-
straints, readily available and cheap such that everyone, all over
the world, could use them as an alternative or complementary
treatment option. A modern approach to chemotherapy may  be
to use lower doses of combinations of chemicals, which work
in complementary ways. Thus, while low-doses of a single com-
pound may  not achieve the full anti-angiogenic function, a mixture
of compounds, or extracts from medical plants, may be able to
speciﬁcally synergize in preventing angiogenesis while avoiding
signiﬁcant side-effects. Such an approach, combining phytochem-
icals in tea and soy extracts has been successfully applied to the
anti-angiogenic treatment of prostate and breast cancer in animal
models [47,49]. Therefore we  aimed at selecting phytochemicals
from as many different classes of natural compounds listed in Sec-
tion 4 as possible.
In line with this rationale, we have identiﬁed 10 natural com-
pounds as potential therapeutic approaches (top row of Table 2)
against the previously identiﬁed targets (top row of Table 1).
These compounds are safer than the synthetic anti-angiogenesis
inhibitors in clinical use today [232,233]–and may  even be con-
sidered as prophylactic (angioprevention) agents. These molecules
were selected because they exhibit pleiotropic functions, i.e. dis-
rupting both inﬂammation and vascularization during tumor onset
and progression and while some of them share molecular targets,
combined they will inhibit a broad spectrum of pro-angiogenic
signaling pathways lowering the risk of adaptive resistance. As
tumors often progressively turn on pro-angiogenic pathways dur-
ing their development to more advanced stages (reviewed in [234]),
which is one possible reason why  many patient do not respond
to single-agent therapies such as anti-VEGF drugs, the cocktail of
10 phytochemical-based therapeutic approaches mentioned here
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would be a more broad-acting treatment option, not least for such
patients that do not respond to commercially available anti-VEGF
drugs.
6. Validation of targets and approaches
Anti-angiogenic agents have demonstrated activity in a broad
spectrum of malignancies. The questions of ﬁnding the best drug,
or combination of drugs, for each patient and how to best evalu-
ate the response to treatment are still not adequately answered.
An alternative to current efforts on targeted therapy development
could be to inhibit an array of pathological targets of tumor blood
vessels such as the 10 targets identiﬁed here (Table 1, top row).
We envision that such a broad approach, simultaneously hitting
multiple or all of these targets of the tumor vasculature at the
same time, would produce an improved therapeutic outcome com-
pared to single-target therapy. The current strategy we  endorse for
further investigation considers a combination of phytochemicals,
identiﬁed to act on more than one or a few of these targets (Table 2,
top row). We believe that this approach circumvents the numer-
ous avenues of emergent resistance, and has the potential to be
an active therapeutic in a broader range of tumors. We  encourage
researchers and clinicians alike to test formulations based on this
natural compound cocktail-principle and in this way  further estab-
lish the paradigm of phytochemicals as anti-angiogenic treatment
options in cancer.
Given the extensive cross-talk between mechanisms regulat-
ing angiogenesis and other aspects of cell biology as well as the
broad effects of phytochemicals, we  believe that it is important
to be able to anticipate synergies that might be achieved through
acting not only on aspects of tumor angiogenesis but also on
other essential aspects of tumor biology such as the “hallmarks” of
cancer. Accordingly, the identiﬁed targets for anti-angiogenic ther-
apy and the therapeutic phytochemical-based approaches were
cross-validated against their effects on other “hallmark” processes,
by undertaking a thorough, qualitative background literature
research. An independent team of scientists consisting of specialists
in various “hallmark” areas speciﬁcally sought to determine the rel-
evance of our identiﬁed targets and the nominated phytochemical
approaches across these other important areas of cancer biology.
The result of this elaborate cross-validation effort is shown in
Tables 1 and 2, for the targets and suggested phytochemical-based
approaches respectively. We found that many of our identiﬁed tar-
gets and approaches were also relevant for other aspects of cancer
biology. In such cases they were noted as having “complemen-
tary” effects (denoted with a + in Tables 1 and 2). In instances
where reports on relevant actions in other aspects of cancer biology
were mixed (i.e. reports showing both pro- and anti-potential), the
effects are considered “controversial” and denoted +/− in the tables.
Finally, in instances where no literature was found to support the
relevance of a target or approach in other aspects of cancer biology,
we consider that there is “no known relationship” and denote this
with a 0 in the tables. We  did not ﬁnd any instances in which our
targets or approaches acted to promote other pathological aspects
of tumor biology. As an example, reducing tumor hypoxia would
also lead to reduced tumor-promoting inﬂammation and therefore
we mark this with a + in the cell intersecting the “(reduce) hypoxia”
column with the “tumor promoting inﬂammation” row in Table 1.
Conversely, our suggested approach resveratrol was found to both
inhibit and induce metastasis and we  therefore denote this as +/−
in the cell intersecting the “resveratrol” column with the “Invasion
and metastasis” row in Table 2.
As it can be determined from closely inspecting these tables,
most of our targets and approaches are found to also inhibit other
essential aspects or hallmarks of tumor pathology. As such, we
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believe that the use of the suggested phytochemical approaches
– or similarly acting derivatives or analogues – would be effective
as alternative anti-angiogenic agents while also inhibiting multi-
ple other aspects of tumor pathology at the same time. Especially
oleanolic acid, silibinin, curcumin, EGCG, melatonin and resvera-
trol, have strong synergistic actions, i.e. anti-tumorigenic effects
in almost all other hallmark areas in addition to being effective
anti-tumor-angiogenic agents. It would be highly important to
experimentally test the effects of such a cocktail of phytochemicals
in pre-clinical and clinical studies in the future.
7. Future directions
The VEGF pathway holds the key in regulating angiogenesis and
targeted therapies against this pathway have been established in
the clinic. However, after initial positive results several studies have
failed to show increased survival rates for many groups of patients
treated with anti-VEGF drugs. It is clear that multiple factors con-
tribute to enabling the angiogenic switch in tumors. However, till
date an overwhelming focus has been placed on blocking the VEGF-
VEGFR2 pathway. Using small synthetic molecules with a broader
target proﬁle, it has been possible to achieve better anti-angiogenic
effects in tumors compared to using speciﬁc antibody based ther-
apeutics. However, the former are more toxic, still not sufﬁciently
effective and therefore other strategies need to be considered.
It is becoming increasingly clear that plant-derived medicinal
compounds may  in many cases be at least as effective in blocking
angiogenesis as the currently used synthetic drugs, while exhibiting
only a fraction of the negative side-effects. Some of these com-
pounds may, however, be more effective in treatment of some
tumors, such as the potential for using phytoestrogens in treat-
ment of ER-positive breast cancer or that of melatonin in treating
cancer in people with disrupted circadian rhythms. Identiﬁcation
of suitable biomarkers for selection of patients to different types of
therapeutic regimens as well as response to treatment has however
so far not been achieved but remain a very important avenue for
future research.
The desired optimal effect of anti-angiogenic treatment is
another issue, which requires further study. Is complete vascular
regression what we aim for? Such an outcome would be expected to
result in extensive tumor hypoxia, radically reduced perfusion and
thus reduced delivery of not only oxygen and nutrients but also
drugs to the tumor tissue. Some studies argue that such a result
of anti-angiogenic treatment may  in fact lead to a more invasive
tumor phenotype and worse prognosis compared to the non-anti-
angiogenesis treated group. Perhaps it would be a better option
to merely reduce the vascular density, improve the structure and
function of tumor blood vessels such that they lose their pathogenic
characteristics and more closely resemble blood vessels in healthy
tissues. Such a phenotype would be expected, however, to lead
to improved perfusion, oxygenation and delivery of nutrients to
the tumor, thereby potentially increasing tumor growth rate. On
the other hand, this would improve the effects of co-administered
chemotherapy, which would also be delivered more effectively
to the tumor, and which would more effectively kill the tumor
cells if these were well nourished and actively proliferating. Per-
haps it should even be considered to withdraw anti-angiogenic
treatment if it is found to result in dramatically reduced per-
fusion and oxygenation of the tumor, at least if such treatment
is used in combination with chemo- or radiotherapy. The phyto-
chemical approaches to inhibit tumor angiogenesis identiﬁed in
Table 2 can, however, in addition to pruning non-perfused and
pathological blood vessels in the tumor, also reduce the detrimental
effects of chemotherapy, leading to improved tolerance and there-
fore improved health and potentially extended survival when used
in combination with classical cytostatic therapies. It should there-
fore be considered whether such compounds could be beneﬁcial
for tumor patients receiving chemotherapy, even if they are also
receiving anti-VEGF drugs as the ones in clinical use today do not
reduce the side-effects associated with chemotherapy.
While many natural compounds have general beneﬁcial effects,
it is clear that some compounds are more effective in cancer
treatment than others. For example, a recent meta-analysis of
randomized placebo-controlled trials testing the effect of dietary
supplementation of multi-vitamins and multi-minerals, failed to
show any effect on cancer mortality suggesting that this is not
a route to prioritize in future efforts [235]. Vitamin E and high
doses of beta-carotene have been shown to increase prostate and
lung cancer risk suggesting that caution is warranted with these
powerful biological components [236,237]. Recently it has become
evident that the function of healthy tissues also relies on the activ-
ity of angiogenic factors. For example, currently used anti-VEGF
drugs cause a marked reduction in vascular density, with a subse-
quent decline in the function of healthy organs such as the thymus
and other endocrine glands, intestine and other parts of the diges-
tive tract, gonads and the kidney [238]. As such, the effects that
we are seeking from the treatment – potent and broad-acting
anti-angiogenic activity – may  end up leading to side-effects. Pos-
sible ways to overcome this issue is by targeted delivery such as
via nanoparticle carriers as discussed above, or by titrating the
amount of phytochemicals given such that it is effective in reduc-
ing/preventing pathological angiogenesis but not high enough to
impair healthy vascular functions. Such an approach could logi-
cally be considered together with the combination of for example
the 10 phytochemicals identiﬁed here in one cocktail where each
compound is selected to complement the other hopefully leading
to synergistic anti-angiogenic effects while maintaining negligible
toxicity. This concept, as well as the identiﬁcation of which tumor
types are more susceptible to such treatment and identiﬁcation of
readouts for efﬁcacy and toxicity, are important areas for future
research.
There are, however, also potential drawbacks associated with
the use of phytochemicals, which needs to be resolved before effec-
tive formulations of such compounds can be achieved. Due to poor
absorption of many phytochemicals in their natural form, it may
be necessary to chemically modify some of the compounds sug-
gested here, or use them in semi-synthetic formulations such as
nanoparticle encapsulations, which would lower their “natural”
status but could promote their therapeutic and pharmacokinetic
proﬁles. How best to take advantage of such derivations or modiﬁ-
cations is still an open question.
8. Final conclusion
The complex and multi-factorial nature of tumor angiogenesis,
especially in advanced tumors, necessitate the use of therapeutic
compounds which act broadly in order to reduce problems with
developing resistance. Cancer is a chronic disorder, which in cases
where no curative treatment exists, has to be treated medically for
a long period of time. Therefore treatment options with very low if
any toxicity are preferred. Cancer is furthermore a growing medical
issue also in developing countries and in societies in which the high
costs associated with cutting edge treatment at modern medical
institutions is prohibitive to the majority of the patients. Therefore
low-cost treatment options have great potential. Phytochemicals
constitute a class of broadly acting and very cheap natural drugs
with very low toxicity especially if given at relatively low doses in
combination. The list of 10 prototypical phytochemical approaches
to inhibit 10 important pro-angiogenic targets in cancer presented
here, constitute a framework for further studies on how to mix  a
Z. Wang et al. / Seminars in Cancer Biology 35 (2015) S224–S243 S235
potentially effective, non-toxic cocktail of natural compounds as
a complement or alternative to other types of anti-cancer drugs
available today. We  hope that this review could serve as a primer
for such investigations, which hopefully could lead to cheaper, safer
and more effective anti-cancer treatment in the future.
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